5-Hydroxyauranetin

5-Hydroxyauranetin

SCHEMBL4066374

COc1ccc(-c2oc3c(OC)c(OC)c(OC)c(O)c3c(=O)c2OC)cc1

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.71
KDM4E B2RXH2 3/20 0.71
GAA P10253 2/20 0.71
TUBB4A P04350 2/20 0.70
TUBB P07437 2/20 0.70
TUBA3C P0DPH7 2/20 0.70
TUBA1B P68363 2/20 0.70
TUBA4A P68366 2/20 0.70
TUBB4B P68371 2/20 0.70
TUBB3 Q13509 2/20 0.70
TUBB2A Q13885 2/20 0.70
TUBB8 Q3ZCM7 2/20 0.70
TUBA3E Q6PEY2 2/20 0.70
TUBA1A Q71U36 2/20 0.70
TUBA1C Q9BQE3 2/20 0.70
TUBB6 Q9BUF5 2/20 0.70
TUBB2B Q9BVA1 2/20 0.70
TUBB1 Q9H4B7 2/20 0.70
ALDH1A1 P00352 3/20 0.66
PKM P14618 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29134048 0.95 MAPT (0.64) MAPTKDM4EGAATUBB4ATUBB
SCHEMBL22361649 0.92 MAPT (0.65) MAPTKDM4EGAATUBB4ATUBB
Calycopterin SCHEMBL2214965 0.90 KDM4E (0.73) MAPTKDM4EGAATUBB4ATUBB
SCHEMBL30049379 0.89 MAPT (0.62) MAPTKDM4EGAATUBB4ATUBB
SCHEMBL28655626 0.89 MAPT (0.65) MAPTKDM4EGAATUBB4ATUBB
SCHEMBL4129003 0.88 MAPT (0.85) MAPTKDM4EGAATUBB4ATUBB
SCHEMBL31558901 0.88 MAPT (0.85) MAPTKDM4EGAATUBB4ATUBB
SCHEMBL28998302 0.88 MAPT (0.63) MAPTKDM4EGAATUBB4ATUBB
SCHEMBL1764438 0.85 ALDH1A1 (0.67) MAPTKDM4EGAATUBB4ATUBB
SCHEMBL28984281 0.84 ALDH1A1 (0.66) MAPTKDM4EGAATUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118121649-A Citrus extract, compound, and use thereof for inhibiting novel coronaviruses 丰苗生物科技股份有限公司 2024-06-04 CN claimed
CN-118121589-A Compounds and their use for inhibiting novel coronaviruses 丰苗生物科技股份有限公司 2024-06-04 CN claimed
CN-118010094-A Liquid phase analysis method for multiple chemical components in Xinhui dried orange peel 江门市五邑中医院 2024-05-10 CN claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
JP-2009506057-A 2009-02-12 JP claimed
EP-1928480-A2 METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION Wellgen, Inc. (US) 2008-06-11 EP claimed
WO-2007024982-A2 METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION WELLGEN, INC. (US) 2007-03-01 WO claimed
CN-118121589-A Compounds and their use for inhibiting novel coronaviruses 丰苗生物科技股份有限公司 2024-06-04 CN disclosed
CN-118121649-A Citrus extract, compound, and use thereof for inhibiting novel coronaviruses 丰苗生物科技股份有限公司 2024-06-04 CN disclosed
CN-118121589-A Compounds and their use for inhibiting novel coronaviruses 丰苗生物科技股份有限公司 2024-06-04 CN disclosed
CN-118010094-A Liquid phase analysis method for multiple chemical components in Xinhui dried orange peel 江门市五邑中医院 2024-05-10 CN disclosed
CN-116609419-A Method for rapidly identifying core production area of pericarpium citri reticulatae 佛山科学技术学院 2023-08-18 CN disclosed
EP-3010499-A1 COMPOSITIONS COMPRISING AT LEAST ONE POLYMETHOXYFLAVONE, FLAVONOID, LIMINOID, AND/OR TOCOTRIENOL USEFUL IN COMBINATION THERAPIES FOR TREATING DIABETES KGK Synergize, Inc. (CA) 2016-04-27 EP disclosed
WO-2014203059-A1 COMPOSITIONS COMPRISING AT LEAST ONE POLYMETHOXYFLAVONE, FLAVONOID, LIMINOID, AND/OR TOCOTRIENOL USEFUL IN COMBINATION THERAPIES FOR TREATING DIABETES KGK SYNERGIZE, INC. (CA) 2014-12-24 WO disclosed
EP-1928480-A2 METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION Wellgen, Inc. (US) 2008-06-11 EP disclosed
WO-2007024982-A2 METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION WELLGEN, INC. (US) 2007-03-01 WO disclosed